GLUNAPACK

Methylene blue is an oxidation-reduction agent.

The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia.

Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market.

Its use as an urinary tract antiseptic has also been investigated.

Methylthioninium chloride (INN, or methylene blue, proposed trade name Rember) is an investigational drug being developed by the University of Aberdeen and TauRx Therapeutics that has been shown in early clinical trials to be an inhibitor of Tau protein aggregation.

The drug is of potential interest for the treatment of patients with Alzheimer's disease.

Indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia.

Other clinical applications of methylene blue include improvement of hypotension associated with various clinical states, an antiseptic in urinary tract infections, treatment of hypoxia and hyperdynamic circulation in cirrhosis of liver and severe hepatopulmonary syndrome, and treatment of ifofosamide induced neurotoxicity.

Guanylate cyclase soluble subunit alpha-2 Inhibitor Nitric oxide synthase 1 Inhibitor.

Following distribution into tissues, rapidly reduced to leukomethylene blue (leucomethylthioninium chloride).

Metabolism to leucomethylene blue may be less efficient in neonates than in older individuals.

Excreted in urine and bile.

About 75% of an oral dose excreted in urine, primarily as stabilized colorless leukomethylene blue.

5–6.5 hours (after Intravenous dose).

Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.

this product contains fructose and should not be taken by persons with hereditary fructose intolerance (HFI).

Do not use if you have allergic reactions to any of the ingredients in this product Ask a doctor before use if you have diabetes Stop use and ask a doctor if symptoms persist, return or get worse If pregnant or breast-feeding, ask a health professional before use.

Keep out of reach of children.

In case of overdose, get medical help or contact a Poison Control Center right away.

Directions for maximum effectiveness never dilute or drink fluids of any kind immediately before or after taking this product repeat dose every 15 minutes or until distress subsides do not take more than 5 doses in 1 hour without consulting a doctor measure only with dosing cup provided.

Dosing cup to be used with this product only.

Do not use with other products. mL= milliliter age dose adults and children 12 years of age and over 15 mL or 30 mL children to under 12 years of age 5 ml or 10 mL.